Weed (BUDZ) Other Working Capital Changes (2025 - 2026)
Weed's (BUDZ) quarterly Other Working Capital Changes came in at -$4005.0 in Q1 2026, down 302.27% year-on-year from $1980.0 in Q1 2025, and down 302.27% quarter-over-quarter from $1980.0 in Q1 2025.
Weed (BUDZ) Other Working Capital Changes (2025 - 2026) Analysis & Trends
Weed's Other Working Capital Changes history runs 2 years deep, the most recent figure standing at -$4005.0 for Q1 2026.
- On a quarterly basis, Other Working Capital Changes fell 302.27% year-over-year to -$4005.0 in Q1 2026; TTM through Mar 2026 was -$2025.0, a N/A change from a year earlier, with the FY2025 full-year figure at -$15961.0, down 1607.18% from the prior year.
- Other Working Capital Changes fell to -$4005.0 in Q1 2026 per BUDZ's latest filing, from $1980.0 in the prior quarter.
- Across five years, Other Working Capital Changes topped out at $1980.0 in Q1 2025 and bottomed at -$4005.0 in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Weed | 3.72 Mn | 3.72 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4,005.00 |
| Mar 31, 2026 | -4,005.00 |
| Mar 31, 2026 | -4,005.00 |
| Mar 31, 2025 | 1,980.00 |
| Mar 31, 2025 | 1,980.00 |
| Mar 31, 2025 | 1,980.00 |